Core Insights - Deerfield Management Company disclosed a significant purchase of Celcuity shares, acquiring 980,470 shares valued at approximately $80.60 million in the fourth quarter of 2026 [1][2] - The total value of Deerfield's position in Celcuity reached $170.95 million at the end of the quarter, reflecting an increase of $134.72 million from the previous quarter, driven by both new purchases and share price appreciation [2] Company Overview - Celcuity Inc. is a biotechnology firm focused on precision oncology, utilizing its CELsignia platform and a pipeline of targeted therapeutics to identify specific cellular drivers of cancer for personalized treatment [5] - The company has a market capitalization of $5.3 billion and reported a net income of -$162.72 million over the trailing twelve months [4] Product and Pipeline - Celcuity's lead drug candidate, Gedatolisib, targets the PI3K and mTOR signaling pathways, which are crucial for cancer growth, by blocking multiple components simultaneously [9] - The FDA has accepted Celcuity's new drug application for Gedatolisib in hormone receptor positive, HER2 negative advanced breast cancer, granting it priority review with a decision date set for July 17, 2026 [10] Market Performance - Celcuity's shares have surged over 1,040% in the past year, significantly outperforming the S&P 500's gain of approximately 19% during the same period [7] - The company is expected to release its upcoming quarterly report soon, and as of September 30, it reported having around $455 million in cash and short-term investments, sufficient to fund operations through the next year [11]

Company Overview - Celcuity is a clinical-stage biotechnology company focused on precision oncology, utilizing its proprietary CELsignia platform to identify abnormal cellular signaling in cancer cells and guide targeted therapy development [6] - The company's pipeline includes innovative diagnostic and therapeutic candidates, with a strategic emphasis on addressing unmet needs in breast and ovarian cancer [6] - As of February 17, 2026, Celcuity shares were priced at $107.32, with a market capitalization of $4.97 billion and a net income of ($162.72 million) [4][8] Recent Developments - On February 17, 2026, Boxer Capital Management, LLC disclosed a purchase of 135,000 shares of Celcuity, valued at an estimated $11.10 million based on quarterly average pricing [1][2] - This acquisition increased Boxer Capital's stake in Celcuity to represent 4.9% of the fund's 13F reportable assets, with the reported value of the position rising to $22.44 million, up $18.00 million from the prior quarter [2][3] - Celcuity shares have experienced a significant one-year price change of 741.1%, outperforming the S&P 500 by 721.3 percentage points [3] Competitive Position - Celcuity develops molecularly targeted therapies for cancer, including the CELsignia diagnostic platform and the investigational drug Gedatolisib for breast cancer treatment [8] - The company’s competitive advantage lies in its integrated approach to diagnostics and therapeutics, supported by partnerships such as its license agreement with Pfizer for Gedatolisib [9]

Summary of Celcuity's Fireside Chat at TD Cowen's 46th Annual Healthcare Conference Company Overview - **Company**: Celcuity - **Focus**: Clinical-stage biotechnology company developing drugs targeting the PAM pathway, specifically the PI3K/AKT/mTOR pathway, which is crucial in oncology [3][3]. Key Trials and Developments - **Ongoing Trials**: - **Phase 3 Trial**: Evaluating Gedatolisib in combination with palbociclib and fulvestrant for women who have progressed on prior CDK therapy [3][3]. - **First-Line Study**: Same drug combination for treatment-naive women with endocrine-resistant metastatic breast cancer [3][3]. - **Earlier Phase Study**: Investigating Gedatolisib with an androgen receptor inhibitor in men with castration-resistant prostate cancer [3][3]. Regulatory Insights - **RTOR Designation**: Celcuity received Real-Time Oncology Review (RTOR) designation, which allows for early submission of data to the FDA, potentially shortening approval timelines for supplemental NDAs [11][11]. - **PDUFA Date**: The priority review is expected to conclude six months after the NDA acceptance, with expectations aligned with historical outcomes for similar drugs [12][12]. Launch Preparation - **Commercial Strategy**: A comprehensive launch plan has been in place for two years, focusing on building a commercial team and infrastructure across various departments [21][21][22][22]. - **Sales Force**: The hiring of sales representatives is expected to begin in the second quarter, aligning with the anticipated launch of Gedatolisib [22][22]. Market Segmentation and Patient Focus - **Target Patient Population**: The primary focus will be on PIK3CA wild type patients, constituting approximately 60% of the market. Data on mutant cohorts will be available prior to the launch, which could enhance market positioning [28][28]. - **Market Dynamics**: Celcuity anticipates a competitive landscape, particularly in the 20% of the market with ESR1 mutations, but believes it holds a significant advantage in the remaining 80% [78][78]. Efficacy and Safety Profile - **Efficacy Expectations**: The company aims for a median progression-free survival (PFS) of at least 10 months, which is statistically significant compared to existing treatments [43][43][45][45]. - **Safety Profile**: Gedatolisib shows a favorable safety profile with low rates of hyperglycemia (less than 10% overall, 2% grade three), contrasting sharply with competitors like alpelisib, which has an 80% hyperglycemia rate [64][64][66][66]. Financial Projections - **Revenue Potential**: Celcuity estimates a potential peak revenue exceeding $10 billion from Gedatolisib in breast cancer treatment, highlighting the significant market opportunity [95][95]. Conclusion - **Underappreciated Aspects**: The size of the patient population eligible for treatment and the potential impact of an effective drug targeting critical disease drivers are seen as key factors that could reshape investor perceptions [96][96].

Core Insights - Celcuity is focused on developing targeted cancer therapies and diagnostic platforms, particularly in precision medicine for oncology [1][6] - Perceptive Advisors increased its stake in Celcuity by 203,881 shares, valued at approximately $16.76 million, reflecting confidence in the company's growth potential [2][7] - Celcuity's share price surged 700% over the past year, indicating strong market performance and investor interest [7][11] Company Overview - As of February 17, 2026, Celcuity's stock price was $107.32, with a market capitalization of $4.97 billion and a net income of -$162.72 million [4] - The company operates a clinical-stage biotechnology model, focusing on proprietary drug candidates and diagnostic technologies, with future revenue expected from licensing and partnerships [8] Product Development - Celcuity's lead drug candidate, Gedatolisib, has received FDA acceptance for a New Drug Application with a PDUFA goal date of July 17, 2026, based on Phase 3 trial data [9][10] - Gedatolisib has been granted Breakthrough Therapy and Fast Track designations, indicating its potential significance in treating advanced breast cancer [9] Investment Implications - Perceptive Advisors' stake in Celcuity represents 5.62% of its reported assets under management (AUM), suggesting a strong conviction in the company's future [7][11] - The upcoming regulatory decision on Gedatolisib is critical for long-term investors, as it will determine the drug's market entry and potential revenue generation [11]

Investment Rating - The report maintains a rating of "Outperform" for the pharmaceutical sector, indicating a positive outlook compared to the broader market [7]. Core Insights - The PAM pathway represents a significant market opportunity, with a potential market size of approximately $10 billion, particularly relevant for breast and prostate cancers [4][13]. - Celcuity's Gedatolisib is highlighted as a promising PAM inhibitor, showing comparable efficacy to existing therapies and is expected to establish a new standard of care in HR+/HER2- breast cancer treatment [21][31]. - The report emphasizes the importance of innovation in the pharmaceutical sector, with a focus on drug development and the integration of advanced technologies [5]. Summary by Sections PAM Pathway Market Potential - The PAM pathway is underdeveloped in solid tumors, with mutations occurring in 38% of cancer patients, covering major types like breast and prostate cancer [4][14]. - Potential revenues from PAM inhibitors are comparable to CDK4/6 and AR therapies, estimated between $8 billion to $10 billion [4][18]. Celcuity and Gedatolisib - Gedatolisib has shown superior efficacy in preclinical studies, with a median progression-free survival (mPFS) of 9.3 months in combination therapy, significantly outperforming standard treatments [22][31]. - The FDA has accepted a new drug application for Gedatolisib, with a priority review status and a target decision date set for July 17, 2026 [31][32]. Hong Kong and Celcuity's Developments - Hong Kong's Hong Kong Medical Index has shown a decline, with specific stocks like Celcuity and Honghua Medicine being highlighted for their innovative approaches in targeting HER2 and PAM pathways [5][70]. - Honghua Medicine is developing a HER2-targeted PAM inhibitor, HMPL-A251, which has demonstrated strong anti-tumor activity in various models and is currently in clinical trials [33][41].

Investment Rating - The report maintains a strong rating for the pharmaceutical sector, indicating it is expected to outperform the market [6]. Core Insights - The targeted PAM pathway represents a potential market of approximately $10 billion, with significant implications for breast and prostate cancer treatments [4][16]. - Celcuity's Gedatolisib is highlighted as a promising PAM inhibitor, showing comparable efficacy to existing therapies and is under FDA priority review with a PDUFA date set for July 17, 2026 [4][37]. - The report emphasizes the importance of innovation and international expansion in the pharmaceutical industry, suggesting that companies focusing on these areas will likely thrive [4]. Summary by Sections Targeted PAM Pathway - The PAM pathway is identified as one of the most underdeveloped targets in solid tumors, with mutations occurring in 38% of cancer patients [4][16]. - Gedatolisib is noted for its effectiveness across various PI3K subtypes and its potential to establish new treatment standards in HR+/HER2- advanced breast cancer [25][37]. - HMPL-A251, developed by Hutchison China MediTech, is a HER2-targeted PAM inhibitor that has shown strong anti-tumor activity in both HER2-positive and low-expressing tumors [41][50]. Market Review and Trends - The report reviews the performance of the pharmaceutical sector from January 26 to January 30, 2026, noting a decline of 3.3% in the CITIC Pharmaceutical Index, which underperformed the CSI 300 Index by 3.4 percentage points [3][60]. - The report highlights the best-performing stocks during this period, including Cap Bio (+26.5%) and Hualan Biological (+12.8%) [3][74]. - The overall valuation of the pharmaceutical sector as of January 30, 2026, is reported at 29.09, reflecting a slight decrease of 0.87% [69].

Core Insights - Evaluate's latest report indicates that ten innovative therapies are expected to receive FDA approval in 2026, covering various fields such as metabolic diseases, oncology, and autoimmune conditions, signaling a shift in treatment paradigms for the coming years [1] Metabolic Diseases - The competition between Novo Nordisk and Eli Lilly in the obesity treatment market is intensifying with the upcoming submissions of CagriSema and Orforglipron, which may reshape the treatment landscape for obesity [5] - CagriSema is a fixed-dose combination therapy of cagrilintide and semaglutide, designed for weekly subcutaneous injection, aiming to effectively regulate metabolism and achieve weight loss through multiple mechanisms [5][6] - Orforglipron is an oral GLP-1 receptor agonist that can be taken at any time of the day, enhancing patient compliance due to its convenient dosing regimen [6] - Clinical trials show that CagriSema achieved a weight loss of 20.4% at week 68 compared to 3.0% in the placebo group, while Orforglipron also demonstrated significant weight loss and improvements in metabolic risk factors [7][8] - Both drugs represent trends in obesity treatment: combination therapy and oral GLP-1 agonists, potentially leading to a more competitive market and increased R&D investments in metabolic disease therapies [9] Cell Therapy - Anitocabtagene autoleucel (anito-cel), a CAR-T therapy targeting BCMA, is expected to provide breakthroughs in treating multiple myeloma, addressing challenges in expanding CAR-T therapy to solid tumors [10] - The innovative D-Domain design of anito-cel improves CAR expression stability and reduces immune-related adverse effects, enhancing its therapeutic efficacy [11] - Clinical data shows a total response rate of 96% and a 24-month overall survival rate of 83% for patients treated with anito-cel, indicating its potential as a durable treatment option [12] Autoimmune Diseases - Brepocitinib and Icotrokinra are poised to optimize precision treatment strategies in autoimmune diseases, moving from broad-spectrum immunosuppression to targeted mechanisms [14] - Brepocitinib is a selective TYK2/JAK1 inhibitor that effectively blocks pathogenic signaling pathways without broadly suppressing normal immune function, showing significant clinical improvement in dermatomyositis patients [15] - Icotrokinra is a first-in-class oral therapy targeting IL-23R, demonstrating significant efficacy in treating moderate to severe plaque psoriasis [16][17] - Both therapies utilize oral administration, enhancing patient compliance and potentially transforming treatment paradigms in autoimmune diseases [19] Breast Cancer Treatment - Gedatolisib, a multi-target PAM inhibitor, aims to address resistance issues in HR+/HER2- advanced breast cancer by fully blocking the PAM pathway [20] - Clinical trials indicate that gedatolisib significantly improves progression-free survival (PFS) in patients with HR-positive, HER2-negative advanced breast cancer [21][22] - Camizestrant, a new oral selective estrogen receptor degrader (SERD), shows promise in treating patients with ESR1 mutations, enhancing treatment efficacy [23][24] - The combination of gedatolisib and camizestrant represents a shift towards multi-pathway combination therapies, providing new treatment avenues for resistant breast cancer patients [26][27] Rare Diseases - Baxdrostat, Ulixacaltamide, and Atacicept are innovative therapies targeting unmet needs in hypertension, essential tremor, and IgA nephropathy, respectively, showcasing the industry's focus on rare diseases [28][35] - Baxdrostat is a selective oral aldosterone synthase inhibitor that has shown significant efficacy in treating resistant hypertension [29][30] - Ulixacaltamide is a selective T-type calcium channel inhibitor that has demonstrated efficacy in treating essential tremor [31][32] - Atacicept targets B-cell activation factors, showing promise in reducing proteinuria in IgA nephropathy patients [33][34] Conclusion - The ten therapies highlighted reflect a shift towards precision medicine, optimized delivery strategies, and improved clinical response rates, marking a transition in biopharmaceutical development towards patient-centered and data-driven decision-making [36]

Core Insights - The 2026 Drugs to Watch report by Clarivate identifies eleven therapies expected to significantly impact clinical practice and achieve strong commercial potential in the coming year [1][2][3] - The report emphasizes the importance of anticipating emerging drug trends and understanding market dynamics to navigate the complex pharmaceutical landscape [3] Metabolic Disease - Orforglipron and Retatrutide, both developed by Eli Lilly, are highlighted for managing obesity and type 2 diabetes mellitus (T2DM) with innovative delivery methods [4][5] - The report projects obesity drug sales to reach USD 150 billion by 2035, emphasizing the need for real-world effectiveness and differentiation in safety and clinical value [16] Rare Conditions - Development in rare diseases is expanding into neurological, psychiatric, and hematologic conditions, requiring targeted engagement and evidence-driven approaches [17] - Therapies like VOYXACT® for immunoglobulin A nephropathy and Relacorilant for ovarian cancer are noted for their potential in these areas [8][13] Oncology - The report features therapies such as Gedatolisib for breast cancer and Tolebrutinib for multiple sclerosis, showcasing advancements in precision oncology [10][9] - The increasing complexity of regulatory pathways in the U.S. and Europe is highlighted as a challenge for companies developing treatments for rare diseases [17] Delivery Innovations - The report underscores the growing importance of delivery innovations, including extended-release formulations and oral alternatives to injectable drugs, which can enhance patient adherence [18] - Mainland China is emerging as a significant market and source of innovation, influencing global strategies in oncology and metabolic disease [18] Methodology and Analysis - The report's findings are based on evaluations from over 160 analysts using integrated, AI-enhanced datasets covering the full R&D and commercialization lifecycle [20][21] - Therapies were selected based on their potential to achieve blockbuster status, defined as reaching USD 1 billion in annual sales within five years [20]

Group 1: Palvella Therapeutics Inc. (PVLA) - Palvella is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with no FDA-approved treatments [2] - Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and has a multi-billion-dollar market opportunity if approved [2] - The stock rose from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, before pulling back to $99.88 [3] Group 2: Cidara Therapeutics Inc. (CDTX) - Cidara is developing a preventive therapy for influenza and has agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion [4] - The stock was trading at $18.98 when profiled on November 21, 2024 [4] Group 3: Celcuity Inc. (CELC) - Celcuity is focused on targeted therapies for oncology, with its lead drug candidate Gedatolisib aimed at breast and prostate cancers [5] - The stock increased from $12.60 on December 4, 2024, to an all-time high of $112.64 on December 12, 2025, before retreating to $99.16 [6] Group 4: Nanobiotix (NBTX) - Nanobiotix is a late-stage clinical biotechnology company developing physics-based therapies for cancer [7] - Its lead candidate, NBTXR3, is undergoing a phase III study for head and neck squamous cell carcinoma, with interim data expected in the first half of 2027 [8] - The stock rose from $12.23 on September 19, 2025, to a high of $30.35 on October 13, 2025, before trading around $21 [10] Group 5: Terns Pharmaceuticals Inc. (TERN) - Terns Pharma is developing small-molecule candidates for serious diseases, with TERN-701 targeting chronic myeloid leukemia [12] - Recent data showed a 75% major molecular response rate among patients receiving higher doses [13] - The stock increased from $5.98 on August 6, 2025, to an all-time high of $48.26 on December 10, 2025, before pulling back to around $40 [14] Group 6: DBV Technologies S.A. (DBVT) - DBV Technologies is developing an epicutaneous immunotherapy for food allergies, with its lead product, the VIASKIN Peanut patch, showing positive results in a phase 3 study [15] - The company aims to submit a Biologics License Application in the first half of 2026, with potential sales of $1.5 billion by 2030 if approved [15] - The stock rose from $10.64 on October 2, 2025, to a high of $26.18 on December 17, 2025, before trading around $19 [16] Group 7: Nutex Health Inc. (NUTX) - Nutex Health reported a significant turnaround from a $424 million net loss in 2022 to a $59 million net income for the nine months ended September 30, 2025 [17] - Revenue increased from $219 million in 2022 to $723.6 million in the first nine months of 2025 [17] - The stock rose from $33.56 on November 25, 2024, to a 52-week high of $193.07 before closing at $182.23 [18] Group 8: Inhibrx Biosciences Inc. (INBX) - Inhibrx is developing biologic therapies for cancer, with Ozekibart showing significant improvement in progression-free survival in chondrosarcoma [19] - The company plans to submit a biologics license application for Ozekibart in the second quarter of 2026 [20] - The stock rose from $18.35 on July 8, 2025, to an all-time high of $94.57 on December 22, 2025, before trading around $77 [21] Group 9: GRAIL Inc. (GRAL) - GRAIL focuses on early cancer detection with its Galleri test, which is not yet FDA-approved [23] - The company expects to submit a PMA for the Galleri test in Q1 2026 [23] - The stock increased from $48.50 on September 26, 2025, to a high of $115.76 on November 25, 2025, before trading around $88 [24] Group 10: Cogent Biosciences Inc. (COGT) - Cogent is developing precision therapies for genetically defined diseases, with Bezuclastinib being its lead candidate [25] - The company submitted its first NDA to the FDA for Non-AdvSM, with additional submissions planned for GIST and advanced systemic mastocytosis [26] - The stock rose from $7.25 on July 2, 2025, to a 52-week high of $43.73 on December 8, 2025, before easing back to around $35 [26] Group 11: Sol-Gel Technologies Ltd. (SLGL) - Sol-Gel has two FDA-approved products for dermatological conditions and is developing investigational products [27] - A phase III trial for SGT-610 is ongoing, with results expected in Q4 2026 [28] - The stock rose from $7.26 on May 7, 2025, to a high of $52.26 on October 6, 2025, before trading around $43 [28] Group 12: Zenas BioPharma Inc. (ZBIO) - Zenas is focused on therapies for autoimmune diseases, with Obexelimab in phase 3 trials for IgG4-RD [29] - Positive data from a phase 2 trial in multiple sclerosis showed a 95% reduction in new lesions [30] - The stock rose from $8.79 on December 17, 2024, to a high of $44.60 on December 24, 2025, before pulling back to around $35 [31]

Core Viewpoint - Celcuity, a company focusing on diagnostic innovations rather than traditional drug development, has seen its stock price surge by 680% over the past year, primarily driven by promising Phase III clinical data for its drug Gedatolisib, which targets a specific type of breast cancer [1][4]. Group 1: Company Overview - Celcuity is not a conventional innovative pharmaceutical company but rather focuses on live tumor technology in the diagnostic field [1]. - The company acquired Gedatolisib, a drug previously abandoned by Pfizer, for a low price of $10 million, which included $5 million in cash and $5 million in equity [9][11]. Group 2: Clinical Data and Drug Efficacy - Gedatolisib has shown significant improvement in progression-free survival (PFS) for patients with ER+/HER2- advanced breast cancer who are resistant to CDK4/6 inhibitors, achieving the best median PFS data ever recorded in this indication [1][11]. - The drug's clinical trial results indicate that its combination therapies can significantly outperform traditional treatments, with a median PFS of 9.3 months for triple therapy compared to just 2.0 months for standard monotherapy [14]. Group 3: Market Potential and Strategic Positioning - The PAM signaling pathway, which Gedatolisib targets, is implicated in various cancers beyond breast cancer, suggesting substantial market expansion potential for the drug [15]. - Celcuity's strategic focus on pathway-based solutions rather than single-target drugs aligns with emerging trends in precision medicine, positioning the company favorably in the competitive landscape [11][12]. Group 4: Competitive Landscape - Pfizer's previous dominance in the CDK4/6 inhibitor market is being challenged by emerging competitors, and Gedatolisib could play a crucial role in reshaping the competitive dynamics in breast cancer treatment [18]. - The potential for Celcuity to become an acquisition target by larger pharmaceutical companies is heightened by Gedatolisib's promising clinical data and its strategic importance in the market [18].